HIV-1 Vif Antibody (319): sc-69731

HIV-1 Vif Antibody (319) is a mouse monoclonal IgG1 kappa light chain antibody that detects HIV-1 Vif protein of HIV-1 origin by western blotting (WB) and immunofluorescence (IF). Anti-HIV-1 Vif antibody (319) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates, providing versatility for different experimental needs. The viral infectivity factor (Vif) is a crucial nonstructural protein that plays a significant role during virus assembly, although its exact mechanism remains to be fully elucidated. HIV-1 Vif (319) monoclonal antibody recognizes Vif protein, which interacts with several key proteins, including Gag, viral protease, HP68, spermine, Triad 3, and RNA, essential for the virus′s life cycle and its ability to evade host immune responses. These interactions not only enhance viral infectivity but also help overcome inhibitory factors present in non-permissive cells, making Vif a target of interest for therapeutic strategies. HIV-1 Vif exists in both soluble cytoplasmic and membrane-bound forms, tightly associating with the cytoplasmic side of cellular membranes, which is critical for function and stability. Vif forms multimers that accumulate in the cytoplasm of infected cells, underscoring importance in viral replication and highlighting potential for targeting in HIV research and treatment development.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HIV-1 Vif Antibody (319) References:

1. The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle.  |  Yang, S., et al. 2001. J Biol Chem. 276: 4889-93. PMID: 11071884
2. Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication.  |  Goncalves, J., et al. 2002. J Biol Chem. 277: 32036-45. PMID: 12039955
3. The role of Vif during HIV-1 infection: interaction with novel host cellular factors.  |  Lake, JA., et al. 2003. J Clin Virol. 26: 143-52. PMID: 12600646
4. Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions.  |  Azimi, FC. and Lee, JE. 2020. Protein Sci. 29: 391-406. PMID: 31518043
5. HIV-1 Vif suppresses antiviral immunity by targeting STING.  |  Wang, Y., et al. 2022. Cell Mol Immunol. 19: 108-121. PMID: 34811497
6. HIV-1 Vif Gained Breadth in APOBEC3G Specificity after Cross-Species Transmission of Its Precursors.  |  Chesarino, NM. and Emerman, M. 2022. J Virol. 96: e0207121. PMID: 34908448
7. The structural basis for HIV-1 Vif antagonism of human APOBEC3G.  |  Li, YL., et al. 2023. Nature. 615: 728-733. PMID: 36754086
8. Structural insights into RNA bridging between HIV-1 Vif and antiviral factor APOBEC3G.  |  Kouno, T., et al. 2023. Nat Commun. 14: 4037. PMID: 37419875
9. Structural basis of HIV-1 Vif-mediated E3 ligase targeting of host APOBEC3H.  |  Ito, F., et al. 2023. Nat Commun. 14: 5241. PMID: 37640699
10. Structural insights into PPP2R5A degradation by HIV-1 Vif.  |  Hu, Y., et al. 2024. Nat Struct Mol Biol. 31: 1492-1501. PMID: 38789685
11. Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains.  |  Goncalves, J., et al. 1995. J Virol. 69: 7196-204. PMID: 7474141
12. Subcellular localization of the Vif protein of human immunodeficiency virus type 1.  |  Goncalves, J., et al. 1994. J Virol. 68: 704-12. PMID: 8289374

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-HIV-1 Vif Antibody (319) has 6 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

HIV-1 Vif Antibody (319) Specifications

Alternate Product Name: HIV-1 Vif

Product Clone Name: 319

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: HIV-1 Vif

Epitope Species: HIV-1

Product Reactivity/Detection: Vif

Species Reactivity/Detection: HIV-1

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IF

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 6 citations in various scientific publications

Available Conjugates/Forms for HIV-1 Vif Antibody (319): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin